Eli Lilly (LLY 0.07%) and Novo Nordisk (NVO 0.73%) are pitted against each other, but only one can be my preferred healthcare stock.
*Stock prices used were the afternoon prices of May 17, 2025. The video was published on May 19, 2025.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Best Healthcare Stocks: Eli Lilly vs. Novo Nordisk
By Parkev Tatevosian, CFA
–
May 21, 2025 at 9:00AM
NYSE: LLY
Eli Lilly
Market Cap
$693B
Today's Change
(0.07%) $0.54
Current Price
$732.50
Price as of August 29, 2025, 3:58 p.m. ET
About the Author
A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history. You'll often find him writing about stocks in the consumer goods and technology sectors.
Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Stocks Mentioned
Eli Lilly
LLY
$732.50
(0.07%)
$0.54
Novo Nordisk
NVO
$56.52
(0.73%)
$0.41
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 Growth Stocks That Could Be Worth $1 Trillion in 5 Years
Why Eli Lilly Stock Trounced the Market on Tuesday
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
One of the Best Stocks to Buy Now?
What's Going on With Eli Lilly Stock?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.